Ultime notizie per Qiagen (NYSE:QGEN) Azioni

Qiagen

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Qiagen NV

Qiagen N.V.

B of A Securities analyst Derik De Bruin maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Buy and raises the price target from $50 to $53.

News

Price Target

Analyst Ratings

QGEN

B of A Securities Maintains Buy on Qiagen, Raises Price Target to $53

<ul>
<li>Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service</li>
<li>Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorization of up to $500 million</li>
</ul>
QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025.
He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate Governance Code indicates that Directors of public companies should not serve more than 12 years for a company on their Supervisory Board.
At the AGM, where 80.4% of QIAGEN's issued shares were represented, shareholders approved all proposed resolutions, including the initiation of an annual cash dividend and a new share repurchase authorization of up to $500 million.
Additionally, Prof. Dr. Elaine Mardis stepped down from the Supervisory Board after deciding not to stand for re-election. Prof. Dr. Mardis brought important scientific expertise to the Board since 2014, especially through her service on the Science &amp; Technology and Human Resources &amp; Compensation Committees.
Following the AGM, QIAGEN's Supervisory Board now consists of eight members, reflecting the implementation of a plan announced in 2024 to return to a size consistent with historical levels and continuing to represent all the necessary expertise to support the future development of QIAGEN in a highly effective manner.
The AGM approved the re-appointment for one-year terms of the following Board members: Dr. Metin Colpan, Dr. Toralf Haag, Prof. Dr. Ross L. Levine, Mr. Bert van Meurs, Ms. Eva van Pelt, Dr. Eva Pisa, Ms. Elizabeth Tallett and Mr. Stephen H. Rusckowski.
Shareholders also approved the initiation of QIAGEN's first-ever annual cash dividend - a milestone that reflects QIAGEN's strong financial position and disciplined capital allocation strategy, which includes dividends in addition to organic investments, value-creating acquisitions and share repurchases.
The first dividend payment will be $0.25 per ordinary share, totaling approximately $54 million, with a record and ex-date of July 2, 2025, and payment date of July 10, 2025.
In addition, the AGM approved a new synthetic share repurchase authorization of up to $500 million, reinforcing QIAGEN's commitment to returning capital to shareholders while preserving financial flexibility to invest in innovation and long-term growth.

Dividends

Buybacks

Management

QIAGEN Elects Stephen Rusckowski As Chairman Of Supervisory Board; Shareholders Approve Annual Cash Dividend Of $0.25/Shr And Synthetic Share Repurchase Authorization Of Up To $500M

Barclays analyst Luke Sergott initiates coverage on Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Overweight rating and announces Price Target of $55.

Initiation

Barclays Initiates Coverage On Qiagen with Overweight Rating, Announces Price Target of $55

<ul>
<li>GENCURIX partnership marks launch of new QIAcuityDx Partnering Program for third-party in vitro diagnostic (IVD) assay development</li>
<li>GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies</li>
<li>Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic laboratories a range of clinical oncology assays</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics.
GENCURIX is the first development partner under QIAGEN's QIAcuityDx Partnering Program. This important advancement marks a significant step towards establishing a broad menu of in vitro diagnostic (IVD) assays on the QIAcuityDx Four platform, increasing access to digital PCR diagnostics.
The new partnership combines QIAGEN's QIAcuityDx digital PCR platform to advance sensitive, cost-effective oncology diagnostics with GENCURIX's expertise in multiplex assay development. The aim is to enable the creation of oncology IVD assays for both tissue and liquid biopsy applications, with flexible commercialization options and global reach through QIAGEN's Partnering Program.

QIAGEN And GENCURIX Partners To Develop Oncology Assays For Use On QIAcuityDx Platform, Digital PCR System Designed For Clinical Diagnostics

<ul>
<li>QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies</li>
<li>Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs</li>
<li>Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples</li>
<li>Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline</li>
</ul>

ILMN

INCY

Reported Sunday, Incyte Taps QIAGEN And Illumina Technology To Advance Precision Diagnostics For CALR-Driven Myeloproliferative Neoplasms

This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples.

Reported Earlier, Tracer Biotechnologies And QIAGEN Partner To Co-Develop Blood-Based MRD Assays For Solid Tumors On QIAcuity Digital PCR Platform

<ul>
<li>Two new partnerships enhance QIAGEN's capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR</li>
<li>Tracer Biotechnologies partnership to develop blood-based minimal residual disease (MRD) tests on QIAcuity digital PCR systems for solid cancer tumors</li>
<li>Collaboration with Foresight Diagnostics aims to develop a kit version of its CLARITY&#x2122; NGS assay for use in lymphoma</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma co-development projects for companion diagnostics. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN's reach in MRD testing and cover solid tumors and hematological cancers.
Minimal residual disease (MRD) testing is becoming a cornerstone of oncology by enabling early detection of cancer recurrence and guiding timely adjustments to therapy from a blood sample. These new partnerships support the growing demand for decentralized, non-invasive tools that advance precision medicine and help deliver more personalized care.
Under the new collaborations:
<ul>
<li>Tracer Biotechnologies, a developer of blood-based molecular diagnostics for cancer, is working with QIAGEN to create companion diagnostics for MRD testing in solid tumors. These assays, designed for use on QIAGEN's QIAcuity digital PCR platform, are designed to enable the use of minimally invasive blood samples to monitor residual disease with high sensitivity. The approach offers a cost-efficient and quick way to support decentralized implementation in clinical laboratories with results comparable to those generated using next-generation sequencing technologies.</li>
<li>Foresight Diagnostics and QIAGEN are creating a kit-based version of the Foresight CLARITY&#x2122; assay, a circulating tumor DNA (ctDNA)-based NGS test for certain types of lymphoma. Transitioning the assay from a CLIA central laboratory service to an in-lab kit is designed to allow for broader clinical access and supports pharmaceutical-sponsored trials with companion diagnostic applications.</li>
</ul>
MRD testing offers a highly sensitive way to monitor treatment response, identify patients at risk of relapse before symptoms appear and inform decisions on therapy usage. It is also emerging as a surrogate endpoint in clinical trials, accelerating drug development and regulatory review.
QIAGEN's MRD portfolio spans sample technologies and testing platforms that support workflows from sample to insight. This includes the QIAsymphony system for automated sample preparation, with the new generation QIAsymphony Connect upgraded version being prepared for launch in late 2025, along with PAXgene blood collection tubes for stabilized blood draws. QIAGEN also offers an extensive range of kits for use on the QIAcuity family of digital PCR instruments as well as the QIAseq targeted gene panels for use on third-party NGS systems. Complementing these solutions is the portfolio of QIAGEN Digital Insights solutions that offer integrated bioinformatics for comprehensive NGS data analysis and interpretation to enable comprehensive MRD results.

QIAGEN Expands Oncology Diagnostics Portfolio With Two Strategic Partnerships To Advance Use Of MRD Testing In Clinical Trials To Support Pharma Co-Development Projects For Companion Diagnostics

Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) to develop and commercialize a kit-based version of Foresight's CLARITY&#x2122; assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological malignancies.
This collaboration combines Foresight's innovative MRD detection technology with QIAGEN's global leadership in molecular diagnostic development and commercialization. Together, the companies aim to lay the groundwork for a standardized, regulated diagnostic kit that, once validated and approved in pharmaceutical-sponsored trials, would be the only circulating tumor DNA (ctDNA)-based MRD assay available as both a central laboratory service and diagnostic kit capable of supporting clinical decision-making and therapeutic strategies for patients with hematological cancers.

Foresight Diagnostics Partners With QIAGEN To Develop, Commercialize Kit-Based Version Of CLARITY Assay For Lymphoma

<ul>
<li>Partnership designed to expand QIAGEN's leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for cancer research</li>
<li>Combines QIAGEN's global reach and automation expertise with ID Solutions' assay development for research purposes and manufacturing strengths</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced a new commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays and customized molecular testing solutions for oncology and other disease areas, to expand the availability of dPCR assays for oncology research applications.
The combination of QIAGEN's global reach and automation expertise with the assay development and manufacturing capabilities of ID Solutions will strengthen QIAGEN's position in oncology research.
Under the agreement, ID Solutions will manufacture and supply dPCR assays for non-clinical research use on QIAGEN's QIAcuity platforms. These assays are optimized to simultaneously detect multiple mutations in cell-free DNA (cfDNA) from plasma and genomic DNA (gDNA) from formalin-fixed, paraffin-embedded (FFPE) tissue. QIAGEN will commercialize these kits starting in Europe as the first region, with the potential for future expansion into other regions.
This agreement supports QIAGEN's strategic focus on accelerating the adoption of the QIAcuity dPCR platform in oncology research. The new assays expand QIAGEN's portfolio, complementing the existing PanCancer Kits for detecting multiple hallmark mutations in DNA from diverse sample types and over 200 LNA (locked nucleic acid) Mutation Assays available via its GeneGlobe platform. This unique platform integrates pre-designed assays with a database of more than 10,000 biological entities, including genes, miRNAs, pathogens and pathways.

QIAGEN Announces New Commercial Partnership And Co-Marketing Agreement With ID Solutions To Expand Availability Of dPCR Assays For Oncology Research Applications

<ul>
<li>Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases</li>
<li>Strengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide with easy-to-use, fast and flexible NGS data interpretation in a rapidly growing market</li>
<li>Franklin complements QCI Interpret, QCI Precision Insights and QIAGEN's leading genetic databases COSMIC and HGMD</li>
</ul>

QIAGEN To Acquire GENOOX For $70M

QIAGEN To Elect Stephen H. Rusckowski As Chairman; To Succeed Lawrence A. Rosen

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) FY2025 expected to be more than $2.35 vs $2.49 Est..

Guidance

Qiagen FY2025  Reaffirms EPS Of $2.35 CER Vs $2.49 Est

QIAGEN At Annual General Meeting Proposes To Introduce A Dividend As Expansion Of Capital Allocation Strategy, Also Seek Authorization For A New $500M Share Repurchase

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) reported quarterly earnings of $0.55 per share which missed the analyst consensus estimate of $0.56 by 1.79 percent. This is a 17.02 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $483.00 million which missed the analyst consensus estimate of $507.25 million by 4.78 percent. This is a 5.28 percent increase over sales of $458.80 million the same period last year.

Earnings

Earnings Misses

Qiagen Q1 Adj. EPS $0.55 Misses $0.56 Estimate, Sales $483.00M Miss $507.25M Estimate

QIAGEN To Propose Initiation Of Annual Cash Dividend Consisting Of $0.25 Per Ordinary Share At Next Annual General Meeting

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

<ul>
<li>QIAcuity digital PCR kits, assays and protocols for lentivirus-based therapies support quality control in cell and gene therapy manufacturing</li>
<li>Expansion underscores the commitment of QIAGEN to help accelerate the development of safe and effective biotherapeutics</li>
<li>New solutions support high-precision analytics for process development, batch release and regulatory compliance and enable a standardized workflow</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as chimeric antigen receptor T-cell (CAR-T), a personalized form of cancer immunotherapy.
This expanded offering supports standardized, high-precision quality control (QC) workflows and strengthens the position of QIAGEN as a trusted partner for quality control, supporting biotech and biopharma companies, Contract Development and Manufacturing Organizations (CDMO) and therapy developers in CGT manufacturing.
"Cell and gene therapy developers face increasing demands for precise, scalable solutions to help ensure therapy safety and efficacy," said Justus Krause-Harder, Vice President and Head of Molecular Tools &amp; Oncology at QIAGEN. "With our expanded dPCR portfolio, we are not only meeting the needs of lentivirus-based therapies but also reaffirming our long-term commitment as a partner for quality control in CGT development and manufacturing."
The additions to QIAGEN's offering of dPCR solutions for lentiviral vectors and their characterization include:
<ul>
<li>The QIAcuity RCL Quant Kit detects replication-competent lentivirus (RCL), a key safety concern in lentiviral vector production. The kit uses clear step-by-step protocols to find even small amounts of RCL, helping therapy developers meet regulations and keep treatments safe.</li>
<li>The new QIAcuity CGT dPCR assays, including eight different wet-lab verified lentiviral targets, are designed for viral vector genome titration (measuring the amount of therapeutic virus particles) and vector copy number (VCN) determination (counting how many copies of a gene are inserted into each cell). The assays offer superior accuracy, reproducibility and speed on the QIAcuity Digital PCR System and enable singleplex and multiplex applications for a streamlined, high-throughput workflow. Together with QIAcuity nanoplates and dedicated master mixes, these assays deliver absolute quantification of viral titer (the concentration of virus particles in a sample) and vector copy number determination, which are crucial for biopharmaceutical manufacturing and quality control processes.</li>
<li>The new CGT Lentivirus Lysis Kit and protocol, combined with QIAcuity CGT dPCR assays, enables vector genome titer quantification with fewer hands-on steps, enhanced accuracy and repeatability. It supports standardized titer quantification from lentivirus particles, promotes robust QC and improved operating procedures, and is ideal for drug development and manufacturing in CGT.</li>
</ul>
These new solutions join the growing portfolio of cell and gene therapy dPCR assays for the biopharma market, including residual DNA quantification kits for commonly used production cell lines such as Human Embryonic Kidney 293 (HEK293), E. coli, and Chinese Hamster Ovary (CHO) cells, mycoplasma quantification kit, adeno-associated virus (AAV) application, viral titer assays and solutions to determine viral vector integrity.

Biotech

General

QIAGEN Expands Digital PCR Portfolio With New Lentivirus Solutions To Strengthen Cell And Gene Therapy Quality Control

Baird analyst Catherine Schulte maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Neutral and raises the price target from $42 to $43.

Baird Maintains Neutral on Qiagen, Raises Price Target to $43

<a href="https://www.bloomberg.com/news/articles/2025-04-15/fivespan-is-said-to-build-stake-in-life-sciences-group-qiagen" title="https://www.bloomberg.com/news/articles/2025-04-15/fivespan-is-said-to-build-stake-in-life-sciences-group-qiagen">https://www.bloomberg.com/news/articles/2025-04-15/fivespan-is-said-to-build-stake-in-life-sciences-group-qiagen</a>

Rumors

Watching Qiagen N.V.; Hearing Fivespan Is Said To Build Stake In Life Sciences Group Qiagen

<ul>
<li>Three new innovative instrument launches expand reach into further lab segments and sample preparation customers as QIAGEN strengthens market-leading position</li>
<li>QIAsymphony Connect set to start phased launch in 2025, first customer sessions being held to highlight enhanced capabilities for oncology and genomics workflows</li>
<li>QIAsprint and QIAmini on track for 2026 launches, expanding options for high- and low-throughput lab demands</li>
</ul>
 &nbsp;

QIAGEN To Launch Three New Sample Prep Instruments By 2026, Expanding Automation From Low To High Throughput Labs

Press Releases

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

QIAGEN announces plans for transition in leadership of Supervisory Board

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

B of A Securities

Barclays

Baird

Morgan Stanley

Comments

Qiagen

Notizie

Ultime notizie per Qiagen (NYSE:QGEN) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO